Nationwide Fund Advisors Sells 1,323 Shares of NewLink Genetics Corporation (NLNK)

Nationwide Fund Advisors decreased its stake in NewLink Genetics Corporation (NASDAQ:NLNK) by 9.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,837 shares of the biotechnology company’s stock after selling 1,323 shares during the period. Nationwide Fund Advisors’ holdings in NewLink Genetics Corporation were worth $309,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of NLNK. Teachers Advisors LLC raised its stake in NewLink Genetics Corporation by 2.8% in the fourth quarter. Teachers Advisors LLC now owns 201,807 shares of the biotechnology company’s stock valued at $2,075,000 after buying an additional 5,500 shares during the last quarter. State Street Corp raised its stake in NewLink Genetics Corporation by 5.7% in the fourth quarter. State Street Corp now owns 430,428 shares of the biotechnology company’s stock valued at $4,422,000 after buying an additional 23,029 shares during the last quarter. Columbus Circle Investors raised its stake in NewLink Genetics Corporation by 155.6% in the first quarter. Columbus Circle Investors now owns 343,041 shares of the biotechnology company’s stock valued at $8,267,000 after buying an additional 208,816 shares during the last quarter. FMR LLC raised its stake in NewLink Genetics Corporation by 119.3% in the fourth quarter. FMR LLC now owns 904,856 shares of the biotechnology company’s stock valued at $9,302,000 after buying an additional 492,330 shares during the last quarter. Finally, Trexquant Investment LP purchased a new stake in NewLink Genetics Corporation during the fourth quarter valued at $200,000. 51.41% of the stock is owned by institutional investors.

Shares of NewLink Genetics Corporation (NASDAQ NLNK) traded up 10.00% during mid-day trading on Friday, hitting $7.70. 1,188,788 shares of the company were exchanged. NewLink Genetics Corporation has a 12-month low of $5.90 and a 12-month high of $25.17. The company’s 50-day moving average price is $7.15 and its 200-day moving average price is $13.92. The firm’s market capitalization is $225.03 million.

NewLink Genetics Corporation (NASDAQ:NLNK) last released its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.21. The business had revenue of $10.37 million during the quarter, compared to analysts’ expectations of $2.65 million. NewLink Genetics Corporation had a negative net margin of 250.91% and a negative return on equity of 61.98%. Equities research analysts predict that NewLink Genetics Corporation will post ($3.05) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Nationwide Fund Advisors Sells 1,323 Shares of NewLink Genetics Corporation (NLNK)” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2017/07/29/newlink-genetics-corporation-nlnk-position-cut-by-nationwide-fund-advisors-updated-updated-updated.html.

Several analysts have recently weighed in on NLNK shares. Zacks Investment Research raised shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Wednesday, June 7th. Cantor Fitzgerald set a $32.00 price objective on shares of NewLink Genetics Corporation and gave the stock a “buy” rating in a report on Sunday, June 4th. Jefferies Group LLC raised their price objective on shares of NewLink Genetics Corporation from $15.00 to $18.00 and gave the stock a “hold” rating in a report on Thursday, April 6th. Robert W. Baird reaffirmed an “outperform” rating and set a $25.00 price objective on shares of NewLink Genetics Corporation in a report on Monday, June 5th. Finally, ValuEngine raised shares of NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a report on Friday, May 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. NewLink Genetics Corporation currently has a consensus rating of “Hold” and a consensus target price of $18.17.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Institutional Ownership by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply